Calquence (acalabrutinib) begins blocking its target in the body within hours of the first dose, but a measurable clinical response typically takes about 3.7 months. That gap between what the drug does at the cellular level and what you and your doctor can see on scans and blood work is worth understanding, because the early weeks of treatment can feel confusing if you don’t know what to expect.
What Happens in the First Hours and Days
Calquence is absorbed quickly. Blood levels of the drug peak roughly 30 minutes after you swallow it. Within about four hours, the drug has bound to virtually all of its target, a protein called BTK that cancer cells in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma rely on to survive and multiply. With BTK blocked, those cells lose a key growth signal.
This effect doesn’t last forever on a single dose. By 24 hours after taking Calquence, some BTK activity starts to reappear. That’s why the drug is taken twice daily: the twice-a-day schedule keeps BTK suppressed above 90% around the clock, which is critical for sustained disease control.
The Lymphocyte Spike in Early Weeks
One of the most unsettling things about starting Calquence is that your white blood cell count may actually go up before it goes down. This is expected and not a sign the drug isn’t working. BTK inhibitors like Calquence work partly by flushing CLL cells out of the lymph nodes and spleen and into the bloodstream, where they eventually die off. This temporary rise in circulating lymphocytes typically peaks around two weeks after starting treatment, then begins to decline and usually returns to your baseline level by about one month.
If your doctor orders blood work during those first couple of weeks, a higher lymphocyte count is normal. It can persist at mildly elevated levels for several months in some people, but it’s considered a pharmacological effect of the drug rather than a sign of disease progression.
When You’ll See a Clinical Response
In clinical trials of previously untreated CLL patients, the median time to a first documented response was 3.7 months. “Response” here means meeting formal criteria: shrinking lymph nodes, improving blood counts, and reducing disease burden to a measurable degree. The range was wide, from as early as 2 months to as long as 22 months, so some people respond much faster or slower than average.
Lymph node shrinkage is one of the earliest visible signs. In studies, greater than 50% reduction in lymph node size occurred in nearly all patients who responded. You may notice swollen nodes in your neck, armpits, or groin becoming smaller within the first few months, though the pace varies. Some people feel the difference before their scans confirm it; others notice nothing obvious until their doctor points to improved imaging or lab results.
Why Response Times Vary
Several factors influence how quickly Calquence works for a given person. Disease burden matters: someone with bulky lymph nodes and very high white counts may take longer to show a measurable response than someone caught earlier. Genetic features of the CLL itself, such as certain chromosome deletions, can also affect how the disease responds.
Drug absorption plays a role too. Calquence needs stomach acid to dissolve properly. Medications that reduce stomach acid, particularly proton pump inhibitors like omeprazole, can cut the amount of Calquence your body absorbs by roughly 40% to 50%. If you’re taking an acid reducer, your oncologist will likely adjust when or how you take Calquence, or switch you to a different type of antacid. This isn’t a minor interaction; it can meaningfully affect how much active drug reaches your system.
What to Expect During Monitoring
Your oncology team will track your progress with periodic blood tests and physical exams during the first several months. Blood counts help gauge how the disease is responding and whether the initial lymphocyte spike is resolving. Imaging, usually CT scans, is used to measure lymph node size at key intervals.
Because the median time to first response is around 3.7 months, don’t expect dramatic confirmation that the drug is working at your first follow-up visit. The early appointments are more about making sure you’re tolerating the medication, watching for side effects like headache, diarrhea, or bruising, and confirming the expected blood count patterns. The real assessment of whether Calquence is controlling your disease comes a few months in.
Calquence is a continuous therapy, meaning you take it for as long as it keeps working. Responses can deepen over time, with some patients achieving better results at the one-year and two-year marks than at their initial response assessment. The drug is not designed to be a short course; staying on schedule with twice-daily dosing is what maintains the constant BTK suppression the treatment depends on.